Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Interim Financials
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(46)
•••
Comment by greaterfoolFredon May 30, 2021 7:26pm
275 Views
Post# 33294610

RE:RE:RE:Interim Financials

RE:RE:RE:Interim Financials
riverrrow wrote: 10 trial sites have managed to treat one patient in the past month. I'm not impressed.

I keep trying to tell you folks to curb your enthusiasm.  Some of you have unreasonable expectations.  This trial is a little more complicated than just a simple drug trial where you ship out some pills and a set of instructions.  We have to ship out sophisticated equipment, then send a technician to set it up and verify its operation.  Then we have to send someone to train Docs how to operate it and use it in treatment.  This all takes time, and with Covid, it takes more time than it should.  Have patience.  It will happen.  We need 35 to 40 treated so that we can throw out the first 12 who were undertreated and have a nice sample to submit to FDA.  Good luck all.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities